Lv21
102 积分 2023-07-04 加入
Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression
19天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
19天前
已完结
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum
25天前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Olaparib efficacy in patients with germline BRCA‐mutated, HER2‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial
1个月前
已完结
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD
2个月前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
2个月前
已完结
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
2个月前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
2个月前
已完结
Should regional nodal irradiation be omitted in patients with node-positive breast cancer converting to node-negative after neoadjuvant chemotherapy?
2个月前
已完结
皖公网安备34019202002308
